Executive Summary of Alcon Inc (ALC)

Alcon Inc stands out as a leading player in the ophthalmology sector, demonstrating consistent revenue growth and strong profitability metrics, though it faces potential risks from market concentration and valuation pressures.

Financial Highlights

As of its latest fiscal year, Alcon reported a revenue of $8.5B and a net income of $1.2B. Trailing-12-month figures show revenue at $8.7B with net income of $1.3B.

Earnings per diluted share reached \$2.50 for the recent fiscal year, with a TTM EPS of \$2.55. Revenue per share on a TTM basis is approximately \$27.8.

Growth Trends and Margins

Revenue CAGR (3-year): 5.8%
EPS CAGR (3-year): 7.2%
Gross margin: 65.4%, showing an upward trend vs. prior year
Net profit margin: 14.1%, stable compared to last year

Profitability and Return Metrics

The company's latest return on equity (ROE) stands at 18.7%, reflecting a positive trend from the previous year's 17.2%.

Cash Flow and Capital Allocation

Alcon generated $1.6B in operating cash flow over the past TTM, with free cash flow at $950M. Capital expenditures were \$600M, dividends paid amounted to \$400M, and share buybacks totaled \$300M.

Earnings Quality and Risk Factors

Concerns include modest accruals and occasional one-time adjustments that slightly impact earnings quality. Cash conversion remains robust, indicating reliable earnings support.

Valuation and Market Sentiment

The current Price-to-Earnings (PE) ratio is 28.4, with a downward trend over the past 1 year and a stabilization over 3 years. Market valuation remains within a reasonable range given steady earnings growth.

Key Risks and Market Concentration

Revenue is notably concentrated among top customers, with the top 3 accounts contributing roughly 25% of total revenue. Market risks include competitive pressures and potential pricing headwinds.

See Revenue & Net Income for detailed financial charts and analysis.

ALCON INC